Notice of Annual General Meeting
The Annual General Meeting of Targovax ASA (the "Company") will be held at the Company’s offices at Lysaker, on 17 March 2021 at 10:00 CET.
As a consequence of the extraordinary situation related to the corona virus the Company encourages shareholders not to attend the general meeting in person, but rather to make use of the ability to cast an advance vote or to vote by proxy.
Corona measures
The Company will hold the general meeting in such a way as to minimize the risk of infection as much as possible and will take such measures as may be necessary to comply with governmental regulations in connection with the general meeting.
The Annual General Meeting will be conducted as briefly as possible, and representation of Targovax's Board of Directors and administration will be kept to a minimum.
No refreshments will be served and necessary infection prevention measures will be taken for shareholders attending in person.
Notice of attendance
Notice of attendance must be received no later than 15 March 2021 at 16:00 CET.
Casting of advance votes and submission of proxies must be received no later than 15 March 2021 at 16:00 CET.
Attached you will find the notice to the General Meeting, including appendices. The notice and appendices will also be made available on Targovax’ website https://www.targovax.com/en/section/governance/general-meetings/.
TRVX - Notice AGM 17 March 2021.pdf
For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com
Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no
IR enquires:
Kim Sutton Golodetz - LHA Investor Relations (US)
Email: kgolodetz@lhai.com
Phone: +1 212-838-3777
About TargovaxActivating the patient's immune system to fight cancer
Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors. Targovax aims to unlock greater clinical benefits in cancer patients by deploying multifunctional platforms to target key immune regulators and oncogenic drivers. Targovax’s focus is to “activate the patient’s immune system to fight cancer”, thus extending and transforming the lives of cancer patients with targeted therapeutic cancer immunotherapies. Targovax’s pipeline aims at different cancer indications, including melanoma, mesothelioma and colorectal cancer. The products are designed to harness the patient’s own immune system to fight the cancer, whilst also delivering a favorable safety and tolerability profile.
Targovax’s lead product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune system to fight the cancer. On the back of very encouraging data in several indications, in monotherapy and in multiple combination, the next development steps for ONCOS-102 will involve a clinical trial with registration intent in checkpoint inhibitor refractory melanoma.